Aetion Announces $36.4 Million in Series B Funding

Aetion, a software platform company delivering real-world analytics and evidence, raised $36.4 million in Series B funding. Led by New Enterprise Associates, the round included new investor Amgen Ventures, alongside existing investors Flare Capital Partners, Lakestar, and Oxeon Ventures.

According to the company, biopharma companies can use the platform to support care access and appropriateness by demonstrating to payers and regulators which medications will best serve their populations. Aetion provides payers the ability to identify clinically- and cost-effective therapies, enabling formulary and plan designs that boost patient outcomes and curb premium hikes.

Aetion will use the funds to meet growing demand and advance the global adoption of real-world evidence for medical treatment approvals and access, and for outcomes-based contracting.